The US FDA has approved ranibizumab for neovascular age-related macular degeneration. However, the off-label use of bevacizumab in the treatment of macular degeneration is inexpensive. This article describes the scenario of bevacizumab in macular degeneration. Macular degeneration or age-related macular degeneration (AMD) is a disease of macula typically develops in older people, leads to vision loss. Frequency evaluations include neovascular AMD and geographic atrophy.
The patients initially show no symptoms but with the progress of time, some patients experience weakening of vision with one or both eyes. The dry (atrophic) macular degeneration affects nearly 80-90% of people. Its cause is unknown and shows slow progression. The wet or neovascular macular degeneration affects 10-15% of people, but it troubles for 90% of all instances of severe vision loss from the AMD. The role of…
